Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use

Bilato C, Baratta R, De Luca L, et al.

Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026;:104872

Real-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease

Rabbani SA, Alkoud HA, El-Tanani M, et al.

Journal of clinical medicine, 2026;15(14)

Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists

Khatami S, Faghihi M, Tavakoli G, et al.

Cardiovascular toxicology, 2026;26(7)

Thermosensitive Hydrogels for Sustained Semaglutide Release: Overcoming Weight Loss Plateau in Diet-Induced Obese Rats

Wang J, Hu H, Long L, et al.

Pharmaceutical development and technology, 2026;:1-27

Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison

Mantovani A, Targher G

Diabetes, obesity & metabolism, 2026

Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk

Inia JA, Droog S, Snabel J, et al.

Diabetes & metabolism journal, 2026

Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight

Lee HM, Marakkalage KG, Kim SH, et al.

International journal of obesity (2005), 2026

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Loomba R, George J, Castera L, et al.

The lancet. Gastroenterology & hepatology, 2026

GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder

Kennedy KP, Bremseth-Vining R, Lynch KG, et al.

The Journal of clinical psychiatry, 2026;87(3)

Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches

Abdallah H, Khalil M, Mahdi L, et al.

Nutrients, 2026;18(14)

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization

Ansari Lari S, Zumot MS, Alrashid MA

Cureus, 2026;18(7):e112694

Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population

Masri R, Kaakour H, Hamdan H, et al.

Endocrinology, diabetes & metabolism;9(4):e70286

Correction to ‘Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis’

Liver international : official journal of the International Association for the Study of the Liver;46(8):e70790

Medical Treatments for Obesity: What Does the Future Have in Store?

Bassatne A, Rizo I

The Journal of clinical endocrinology and metabolism, 2026

The Crunchometer, a low-cost, open-source acoustic analysis of feeding microstructure

Gil Lievana E, Arroyo B, Pérez-Ortega J, et al.

eLife, 2026;14

On indirect negative inotropic effects of muscarine in the isolated human atrium

Neumann J, Hofmann B, Hadova K, et al.

Naunyn-Schmiedeberg's archives of pharmacology, 2026

Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation

Lipska KJ, Zawack K, Yan L, et al.

Annals of internal medicine, 2026

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials

Alhazmi A, le Roux CW

Diabetes, obesity & metabolism, 2026

Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes

Polsky S, Beck E, Shah A, et al.

Diabetes technology & therapeutics, 2026;:15209156261468108

Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Kanbay M, Shah E, AlShiab R, et al.

Diabetes, obesity & metabolism, 2026